RDUS still maintains analyst buys/PT of >60 wth their new approved drug, Tymlos which will start selling later this year (hopefully) and has strong advantages over current Forteo. Nevertheless, the market wayyyy overreacted to news of a new CEO & look at the RSI now! I just wrote Jan 2018 35 puts and about to write July & Aug. 40s for easy premium or cheap shares...
